Many patients are using peptide-based treatments in the United States even when several of these products are not approved by the Food and Drug Administration (FDA), according to recent medical and regulatory updates.
Peptides are small chains of amino acids that can affect hormones and cell signalling. Some are approved and widely used in medicine, such as insulin and GLP-1 drugs like semaglutide, which are prescribed for diabetes and weight loss.
However, many other peptides promoted for weight loss, recovery, and anti-ageing are not FDA-approved for general medical use. These include compounds such as BPC-157, TB-500, and others that are often discussed in fitness and online wellness communities.
Use continues despite regulatory limits
Recent discussions from US regulatory advisory groups show that several peptides are under review for possible use in compounded medicines made by licensed pharmacies. In 2026, an FDA advisory panel recommended allowing a number of peptides to be considered for compounding, but this is not the same as full approval.
The FDA has not approved most of these compounds for widespread medical use, and officials continue to say that evidence on safety and effectiveness is limited for many of them.
Despite this, demand is increasing. Doctors report that patients are asking about peptides more often, especially after seeing them promoted on social media and wellness websites.
Concerns about safety and sourcing
Health experts warn that many non-approved peptides sold online or through unofficial clinics may not meet medical safety standards. Risks include incorrect dosing, contamination, and unknown long-term effects.
Some products are also sold in unregulated or “grey market” channels, where quality control is inconsistent.
Regulatory debate continues
The growing use of peptides has led to ongoing debate in the US about how they should be regulated. Some experts support allowing limited access through controlled pharmacy compounding to reduce unsafe use. Others say more clinical data is needed before expanding access.
Outlook
FDA reviews of several peptides are still ongoing, and further decisions are expected in the coming years.
For now, experts say patient demand is rising faster than regulation, and many people are already using peptides regardless of FDA approval status.